NCT06838208View on ClinicalTrials.gov

Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC

PHASE2RecruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

February 25, 2025

Primary Completion Date

March 1, 2027

Study Completion Date

April 1, 2028

Conditions
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Interventions
DRUG

Tislelizumab, Carboplatin /Cisplatin, Etoposide

Induction therapy stage LDRT: lung lesions, 15Gy/5f; Maintenance therapy phase SBRT: The main residual lesions evaluated by the investigators, 30Gy/5f；

Trial Locations (1)

230031

RECRUITING

Anhui Cancer Hospital, Hefei

All Listed Sponsors
lead

Anhui Provincial Cancer Hospital

OTHER